Medtronic Just Posted Its Best Quarter in 2.5 Years
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Medtronic (NYSE: MDT | MDT Price Prediction) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026. The medical device giant beat Wall Street expectations with non-GAAP EPS of $1.36 versus the $1.35 consensus, while revenue reached $9.02 billion against $8.99 billion estimates.
Cardiac Ablation Drives Outperformance
The Cardiovascular Portfolio led the quarter with 13.8% reported growth, powered by an exceptional 80% surge in Cardiac Ablation Solutions. U.S. cardiac ablation revenue exploded 137%, driven by the company’s pulsed field ablation (PFA) portfolio. Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes posted 8.3% organic growth to $796 million.
Regulatory Wins and M&A Activity
Medtronic achieved critical milestones, including CE Mark approval for Sphere-360 and FDA clearance for the Hugo robotic-assisted surgery system, with first cases completed in February 2026. The company also secured FDA clearance for the Stealth AXiS spinal system. The strategic acquisition of CathWorks (coronary/renal denervation) and strategic investment in Anteris (structural heart) expand the portfolio.
Profitability and Outlook
Non-GAAP operating profit reached $2.18 billion with a 24.1% margin, though GAAP net income declined 11.67% year-over-year to $1.14 billion. CEO Geoff Martha emphasized confidence in the trajectory: “Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth.”
Management reiterated full-year guidance for approximately 5.5% organic growth and EPS of $5.62 to $5.66, which includes a $185 million tariff impact. Shares traded at $95.88 as of February 17, up 3.5% over the past year but down 5.5% in the past week.
Contact [email protected] for any questions or corrections.






